| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
The efficacy and safety of allergen specific sublingual immunotherapy (SLIT) are established. However, SLIT requires a long administration period of about for three years. I planned the use of the immunoregulation action of the NKT cell for treatment of allergic rhinitis. In this study, I administered ovalbumin (OVA) and liposome including α-GalCer into the oral submucosa of allergic rhinitis mouse model. Administration of OVA/ liposome pulsed α-GalCer suppressed antigen-specific responses. The new therapy for allergic rhinitis using liposome and NKT cell-mediated immunity system may enhance therapeutic efficacy and shorten duration of treatment.
|
